Member Info for ALB1

I know someone who works for GLEN, and although I'm not in here I'm debating it right now ,, as if she is right and negotiations are currently ongoing into developing the resource here and with it being close to a possible deal then it's an outright 10x plus possibility here!. Does anyone have figures for resource value here?.

Drayson & the BOD said last November when at £1 per share that SENS was way undervalued... and then they said discussions were ongoing, however no update in 6 months?.. Strange!. Will soon run out of cash again as no revenue and the costs with 170 staff etc must be huge,. I cannot believe that the BOD are content with the current SP decline and the fact that they further cannot even provide an update on the current trading.

There's always a reason for such dramatic falls in the SP of a coy, the MM's are aware,,,so why not tell the truth BOD.!

Sell Below 10p broken, 5p coming....

Don't blame you stick, it's not worth anymore than a few pence per share, and that's a big gamble too!. To many people on very high salaries with no revenue = a delusional BOD , big mistake by the loan providers , and a fire sale if they can actually sell it on. If not lots of job losses soon and administrators in.

Is the current cash value therefore 3p to 5p is where this is heading. I may have a dabble at that level once the additional warrants and loan is taken on. BOD need replacing, especially with their huge salaries. £1.50 to 10p in 6 months!.

Remember this RNS , unreal!

Oxford, U.K., 2 November 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the ethical clinical AI company, today provides an update to the strategic announcement on 19 July 2021.

The Company's Chief Executive Officer and its largest shareholder, Lord Paul Drayson, has approached the Sensyne Board requesting approval to speak to potential third party investors in order to pursue a potential management buyout of the Company. In order to maximise value for all of the Company's shareholders, the Board has appointed J.P. Morgan Cazenove and Peel Hunt to consider a management buyout proposal ("MBO") (should one be forthcoming) and explore other buyer interest alongside considering other strategic options that would allow Sensyne to scale more rapidly, with these including strategic investment or the continued pursuit of a secondary US listing.

The Board believes that the current market value of the Company does not reflect the fair value of the electronic patient record ("EPR") health data to which the Company has access through its strategic partnership agreements with UK NHS Trusts and US health systems. Being undervalued means that Sensyne cannot execute on opportunities that may create novel treatments for patients. The Company currently has access to a data set of 22.5 million such records and has through its agreement with OMNY Inc the potential to access a further 22 million US patient records, and access to approximately 42 million clinical trial records through its agreement with Phesi Inc.

The Board intends to seek an outcome which respects the unique heritage and culture of the Group, its commitment to the ethical application of clinical AI to patient data and enables the Company to deliver maximum value to all stakeholders and continue to prosper in the long-term.

Since inception, and more recently since the IPO, Sensyne has developed significant AI and data science expertise through its collaborations with NHS Trusts, academic institutions and pharma groups, and has established access to significant patient data on an anonymised basis through agreements with multiple UK NHS Trusts and US Healthcare systems. By applying AI and machine learning methods to what the Company sees as one of the deepest, longitudinal patient datasets in healthcare, Sensyne generates new and otherwise unidentifiable insights of value to advance patient care and pharmaceutical research.

Through its Life Sciences and Healthcare Products divisions, Sensyne works towards connecting patients, clinicians and researchers, which collectively helps healthcare professionals deliver better patient care while curating vital data to support the next generati

Not much cash left now, Sens will soon ask for the 2nd tranch/loan note. Once they spend that it's administrators in/MBO. I can only refer people to the BOD's statement 2.11.21 when the SP was £1. The SP is now 11p.!! . All a BS story here.

Oxford, U.K., 2 November 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the ethical clinical AI company, today provides an update to the strategic announcement on 19 July 2021.

The Company's Chief Executive Officer and its largest shareholder, Lord Paul Drayson, has approached the Sensyne Board requesting approval to speak to potential third party investors in order to pursue a potential management buyout of the Company. In order to maximise value for all of the Company's shareholders, the Board has appointed J.P. Morgan Cazenove and Peel Hunt to consider a management buyout proposal ("MBO") (should one be forthcoming) and explore other buyer interest alongside considering other strategic options that would allow Sensyne to scale more rapidly, with these including strategic investment or the continued pursuit of a secondary US listing.

The Board believes that the current market value of the Company does not reflect the fair value of the electronic patient record ("EPR") health data to which the Company has access through its strategic partnership agreements with UK NHS Trusts and US health systems. Being undervalued means that Sensyne cannot execute on opportunities that may create novel treatments for patients. The Company currently has access to a data set of 22.5 million such records and has through its agreement with OMNY Inc the potential to access a further 22 million US patient records, and access to approximately 42 million clinical trial records through its agreement with Phesi Inc.

Cannot see any of the interest that was mentioned here actually materialise. They said last November at £1 per share that SENS was way undervalued... and then they said discussions were ongoing, however no update in 5 months?.. Strange!. Will soon run out of cash again as no revenue and the costs with 170 staff etc must be huge.

My only hope is the BOD & Drayton lose all for their totally false statements. In fact I hope Sens is closed down as the company has totally deceived people.

At £1 per share back in Nov 2021 the Bod said sens was undervalued and a FSP began... since then the SP has fallen to 11p !!... no offers, no FSP updates no nothing but high costs and soon to spend up again. If this was a bargain as folk suggest it would have been took over long ago. The only satisfying element to this company is that mr Drayson and all the cronies involved here will lose a fortune.

Wouldn't surprise me here, big players and interested parties seem to want Mccolls bust and then to probs buy out on the cheap!, just as things will turn around too!. I hope the BOD realise this and don't let them get away with it.

Cannot see any of the interest that was mentioned here actually materialise. They said last November that discussions were ongoing however no update in 4 months?.. Strange!. Will soon run out of cash again as no revenue and the costs with 170 staff etc must be huge.

A Series of contract wins would also dramatically change the fortune's of Sens here. IMO it's either a takeover or it's a recovery share to the 75p area. Have to be patient though and give it a couple of months for either to come out.

Hello billy, I now believe that the SP is being held low pending an offer. 65p to 75p.

Fasten seat belts time, big news coming here!

Been told that active discussions are ongoing ...and a 70p takeout is quite possible!!

If there's an offer - maximum 25p.

I'm sure they'd be interest to buy... It's at what price?.. What is sens really worth?, we know £90m spent to date, huge tax losses could be claimed back £80m or so, however spend/staff costs are quite high too. If revenue was guaranteed different story here and that's why the BOD stated it was undervalued at £1 ps. But the revenue didn't happen!.

Might get 15p donmac, no interest what so ever here.

If any genuine holders have questions such as -
1. Do the BOD still think sens was undervalued at £1 PS,
2. Why no transparency on the FSP?
3. Why were LTH unable to join in on the 10p warrants.
4. Is a MBO still being considered.

Then you can ask -A video link for virtual attendance is being made available to provide shareholders with the opportunity to listen to the General Meeting and to have their questions answered. If you would like to join the video conference, please contact CSCSensynehealth@consilium-comms.com by close of business on Wednesday, 9 February 2022.

After 3 months or so,, some kind of firm takeover news would have issued if parties were interested. The SP is at 18p precisely for that reason !. No other contract news also?.. I predict a 10p MBO once confirmed end of FSP.

And for the BOD to say this was undervalued at £1.00 then out of cash 2 months later !!